Bedaquiline reprograms central metabolism to reveal glycolytic vulnerability in Mycobacterium tuberculosis

Bedaquiline reprograms central metabolism to reveal glycolytic vulnerability in Mycobacterium tuberculosis

Bedaquiline (BDQ) is a known tuberculosis treatment, but the precise mechanism of cell death is unclear. Here, the authors explore the metabolic profiles of M. tuberculosis upon BDQ treatment and find reliance on glycolysis and synergistic cell death when oxidative phosphorylation is also targeted.

Bibliographic Details
Main Authors: Jared S. Mackenzie, Dirk A. Lamprecht, Rukaya Asmal, John H. Adamson, Khushboo Borah, Dany J. V. Beste, Bei Shi Lee, Kevin Pethe, Simon Rousseau, Inna Krieger, James C. Sacchettini, Joel N. Glasgow, Adrie J. C. Steyn
Format: Article
Language:English
Published: Nature Publishing Group 2020-11-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-020-19959-4

Internet

https://doi.org/10.1038/s41467-020-19959-4

Similar Items